SHENK, KEVIN D.,PARLATI, FRANCESCO,BENNETT, MARK K.
申请号：
CA2791651
公开号：
CA2791651C
申请日:
2011.03.01
申请国别(地区):
CA
年份:
2019
代理人:
摘要：
One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
